WHO Covid 19 - Neurological Abnormalities in SARS-CoV-2 ICU Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

20 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-10-13

Study Completion Date

2021-08-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The SARS-CoV-2 epidemic is leading to a large number of patients in intensive care units due to severe hypoxemic pneumonia. After an acute phase that may require controlled mechanical ventilation and deep sedation, removal of sedation often reveals a pathological awakening in the vast majority of patients. This encephalopathy state remains, to date and to our knowledge, unexplained. Clinical features do not appear to fully correlate with regular delirium. This encephalopathy might be explained by deep and prolonged hypoxemia, a wide use of sedation drugs, systemic inflammation or the hostile ICU environment.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is intended to investigate neurological abnormalities associated with SARS-CoV-2 infection. Complete daily neurological examinations will be routinely conducted in intensive care unit patients. Specific biological analyses will also be performed in these patients by collecting additional blood samples from an arterial or central catheter, every 2 days. These clinical and biological examinations will be continued throughout patient's stay in the intensive care unit.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

SARS-CoV-2 Infection Intensive Care Unit Patient Neurological Abnormality Delirium Encephalopathy

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

SARS-CoV-2 infection Intensive care unit patient Neurological abnormalities Delirium Encephalopathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 18 years old
* COVID-19 positive patient (positive RT PCR, nasopharyngeal or tracheal)
* Patient admitted in an intensive care unit of the department of Anesthesia, Critical Care and Perioperative of Clermont-Ferrand University Hospital
* Patient with an arterial or central catheter to perform blood samples collection

Exclusion Criteria

* Patient or family member's refusal to participate
* Neuropsychiatric history that may interfere with neurological evaluations in the intensive care unit
* Patient not affiliated with French social security insurance
* Patient under legal guardianship

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHU

Clermont-Ferrand, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Lise Laclautre

Role: CONTACT

Phone: +33 4 754 963

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Thomas Godet

Role: primary

Benjamin Rieu

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NeuroCovid-RNI 2020 GODET

Identifier Type: -

Identifier Source: org_study_id